TipRanks
Advertisement
Advertisement

INKT Stock Latest News

MiNK Therapeutics to present data on cancer research at SITC 2026
The FlyMiNK Therapeutics to present data on cancer research at SITC 2026
3d ago
INKT
MiNK selected for ARPA-H-Funded initiative to advance room-temp cell therapy
PremiumThe Fly
MiNK selected for ARPA-H-Funded initiative to advance room-temp cell therapy
5d ago
INKT
MiNK Therapeutics Earnings Call Highlights ARDS Push
PremiumCompany Announcements
MiNK Therapeutics Earnings Call Highlights ARDS Push
1M ago
INKT
Analyst Maintains Buy on MiNK Therapeutics, Reiterates $35 Price Target on Promising Early Data for agenT-797
PremiumRatings
Analyst Maintains Buy on MiNK Therapeutics, Reiterates $35 Price Target on Promising Early Data for agenT-797
2M ago
INKT
MiNK Therapeutics presents early observations from Phase 2 agenT-797 trial
PremiumThe Fly
MiNK Therapeutics presents early observations from Phase 2 agenT-797 trial
2M ago
INKT
MiNK Therapeutics Advances Phase 2 Trial of agenT-797 in Severe Pneumonia: What Investors Should Watch
PremiumCompany AnnouncementsMiNK Therapeutics Advances Phase 2 Trial of agenT-797 in Severe Pneumonia: What Investors Should Watch
3M ago
INKT
MiNK Therapeutics Stockholders Back Directors, Ratify Auditor
Premium
Company Announcements
MiNK Therapeutics Stockholders Back Directors, Ratify Auditor
3M ago
8K
INKT
MiNK Therapeutics doses first patient in agenT-797 trial
Premium
The Fly
MiNK Therapeutics doses first patient in agenT-797 trial
4M ago
INKT
MiNK Therapeutics reports new data on agenT-797 at ATS 2026
PremiumThe Fly
MiNK Therapeutics reports new data on agenT-797 at ATS 2026
5M ago
INKT
Mink Therapeutics’ Earnings Call: High Promise, Tight Runway
PremiumCompany Announcements
Mink Therapeutics’ Earnings Call: High Promise, Tight Runway
5M ago
INKT
MiNK Therapeutics initiates agenT-797 clinical trial
PremiumThe Fly
MiNK Therapeutics initiates agenT-797 clinical trial
5M ago
INKT
Buy Rating on MiNK Therapeutics Driven by Promising Phase 2 Survival Benefit and Immune Activation in PD-1–Refractory Gastric Cancer
PremiumRatings
Buy Rating on MiNK Therapeutics Driven by Promising Phase 2 Survival Benefit and Immune Activation in PD-1–Refractory Gastric Cancer
6M ago
INKT
MiNK Therapeutics management to meet virtually with B. Riley
PremiumThe FlyMiNK Therapeutics management to meet virtually with B. Riley
6M ago
INKT
MiNK Therapeutics: Buy Rating on Emerging Pulmonary Franchise and Key agenT-797 ARDS Catalyst
Premium
Ratings
MiNK Therapeutics: Buy Rating on Emerging Pulmonary Franchise and Key agenT-797 ARDS Catalyst
6M ago
INKT
MiNK Therapeutics’ Earnings Call Signals High-Risk Upside
Premium
Company Announcements
MiNK Therapeutics’ Earnings Call Signals High-Risk Upside
6M ago
INKT
INKT Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
INKT Upcoming Earnings Report: What to Expect?
6M ago
INKT
MiNK Therapeutics Explores Strategic Partnerships and Trial Collaborations
PremiumCompany Announcements
MiNK Therapeutics Explores Strategic Partnerships and Trial Collaborations
6M ago
8K
INKT
MiNK Therapeutics Appoints New Principal Financial and Accounting Officers
PremiumCompany Announcements
MiNK Therapeutics Appoints New Principal Financial and Accounting Officers
7M ago
8K
INKT
3 Penny Stocks to Watch Now, 3/11/26
PremiumMarket News
3 Penny Stocks to Watch Now, 3/11/26
7M ago
ATPC
INKT
Morning News Wrap-Up 3/10/26: Tuesday’s Biggest Stock Market Stories!
PremiumMarket NewsMorning News Wrap-Up 3/10/26: Tuesday’s Biggest Stock Market Stories!
7M ago
GD
AMD
MiNK Therapeutics: Buy Rating Backed by Non-Dilutive PRAME iNKT Partnership and Expanded Oncology Upside
Premium
Ratings
MiNK Therapeutics: Buy Rating Backed by Non-Dilutive PRAME iNKT Partnership and Expanded Oncology Upside
7M ago
INKT
Why Is MiNK Therapeutics Stock (INKT) Up Today?
Premium
Market News
Why Is MiNK Therapeutics Stock (INKT) Up Today?
7M ago
INKT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >